双环醇治疗非酒精性脂肪性肝病疗效的meta分析

肝脏 ›› 2021, Vol. 26 ›› Issue (4): 424-428.

双环醇治疗非酒精性脂肪性肝病疗效的meta分析

李贲, 纪世博, 赵莹莹, 程丹颖, 李炜, 欧蔚妮, 邢卉春

100015 首都医科大学附属北京地坛医院肝病三科

收稿日期:2020-07-06 发布日期:2021-05-22
通讯作者: 邢卉春, Email:hchxing@sohu.com
基金资助:
北京市医院管理局扬帆计划(XMLX201837);十三五艾滋病和病毒性肝炎等重大传染病防治(2018ZX10302206－003-006);北京市医院管理局消化内科学科协同发展中心项目(XXT26);首都卫生发展科研专项(首发2020-1-2171)

The effect of bicyclol on nonalcoholic fatty liver disease:A meta-analysis

LI Ben, JI Shi-bo, ZHAO Ying-ying, CHENG Dan-ying, LI Wei, OU Wei-ni, XING Hui-chun

Central of Liver Diseases Division 3, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

Received:2020-07-06 Published:2021-05-22
Contact: XING Hui-chun, Email:hchxing@sohu.com

摘要/Abstract

摘要： 目的探讨双环醇治疗非酒精性脂肪性肝病(NAFLD)患者的有效性。方法从PubMed、Medline、Embase 英文数据库以及万方数据库、维普中文网、知网中文数据库检索有关双环醇和NAFLD的相关文献, 筛选文献后并提取数据, 时限设定为建库至2019年12月, 采用Cochrane偏倚风险表的评价文献的质量, 采用RevMan5.3软件进行统计学分析。结果共纳入8篇文献, 共873例患者, 其中试验组446例, 对照组427例, 在双环醇治疗2个月至6个月后, NAFLD患者血清ALT明显下降(WMD=-13.19, 95％CI:-22.0～-4.37, P=0.003);在治疗24周至6个月后, NAFLD患者血清TG明显下降(WMD=-0.38, 95％CI:-0.74～-0.02, P=0.04);在治疗24周至6个月后, NAFLD患者血清TC明显下降(WMD=-0.21, 95％CI:-0.37～-0.06, P=0.007)。结论双环醇可有效降低NAFLD患者血清中ALT、TG、TC水平。

关键词: 双环醇, 非酒精性脂肪性肝病, 疗效, meta分析

Abstract: Objective To investigate the efficacy of bicyclol in the treatment of transaminase and lipid in patients with nonalcoholic fatty liver disease (NAFLD), and to search for related literature for meta analysis.Methods From PubMed, MEDLINE, EMBASE English database, Wanfang database, VIP Chinese network and HowNet Chinese database, the relevant literatures of bicyclol and NAFLD were searched. After literature screening and data extraction, the time limit was set as from the establishment of the database to December 2019. Cochrane bias risk table was used to evaluate the quality of literature, and Revman 5.3 software was used for statistical analysis. Results In this study, 8 articles were included, and 873 patients were enrolled, 446 in the experimental group and 427 in the control group. After 2-6 months of bicyclol treatment, serum ALT of NAFLD patients decreased significantly[WMD=-13.19, 95％CI:-22.0～-4.37, P=0.003];After 2-6 months of treatment, the serum TG of NAFLD patients decreased significantly[WMD=-0.38, 95％CI:-0.74～-0.02, P=0.04];After 2-6 months of treatment, the serum TC of NAFLD patients decreased significantly [WMD=-0.21, 95％CI:-0.37～-0.06, P=0.007].Conclusion Bicyclol can effectively reduce the levels of ALT, TG and TC in serum of patients with non-alcoholic fatty liver disease.

Key words: Bicyclol, Nonalcoholic fatty liver disease, Efficacy, Meta analysis

李贲, 纪世博, 赵莹莹, 程丹颖, 李炜, 欧蔚妮, 邢卉春. 双环醇治疗非酒精性脂肪性肝病疗效的meta分析[J]. 肝脏, 2021, 26(4): 424-428.

LI Ben, JI Shi-bo, ZHAO Ying-ying, CHENG Dan-ying, LI Wei, OU Wei-ni, XING Hui-chun. The effect of bicyclol on nonalcoholic fatty liver disease:A meta-analysis[J]. Chinese Hepatolgy, 2021, 26(4): 424-428.

参考文献

[1] George J, Anstee Q, Ratziu V, et al. NAFLD:the evolving landscape[J]. J Hepatol, 2018, 68:227-229.
[2] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南.临床肝胆病杂志, 2010, 26:120-124.
[3] Ybunossi ZM, Koenig AB, Abdelatif D, et al.Global epidemiology of nonalcoholic fatty 1iver disease-meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology, 2016, 64:73-84.
[4] 范建高.中国非酒精性脂肪性肝病的流行病学.中国医师进修杂志, 2010:4-6.
[5] Chalasajli N, Youllossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease:practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.Am J Gastroenterol, 2012, 107:811-826.
[6] Chalasani N, Younossi Z, Lavine JE, et al.The diagnosis and management of nonalcoholic fatty liver disease.Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018, 67:328-357.
[7] 朱越. 双环醇片治疗非酒精性脂肪性肝炎. 世界华人消化杂志, 2005, 13:139-140.
[8] 徐芸, 文小岗, 王振豫, 等. 双环醇片治疗非酒精性脂肪性肝病疗效分析. 肝脏, 2006, 11:339-341.
[9] 赵培利, 王玉华, 刘泉, 等. 百赛诺治疗非酒精性脂肪50例疗效观察. 河北中医, 2009, 31:1593-1594.
[10] 苏红领, 朱玉侠, 高正军, 等.双环醇与多烯磷脂酰胆碱治疗非酒精性脂肪肝的疗效比较. 中华肝脏病杂志, 2011, 19:552-553.
[11] 李方学, 张为卿, 李莉, 等.双环醇治疗非酒精性脂肪性肝炎的临床观察. 临床药学, 2011, 7:31-32.
[12] 李明, 杨凡, 徐飞, 等.双环醇联合多烯磷脂酰胆碱治疗老年非酒精性脂肪肝性肝病的疗效分析. 中国医师进修杂志, 2014, 37:1-3.
[13] Han Y, Shi JP, Ma AL, et al. Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose. Clin Drug Investig, 2014, 34:1-7.
[14] 石柳, 汤建华, 温建军, 等.双环醇片对非酒精性脂肪肝患者肝功能及血管内皮功能的影响. 当代医学, 2018, 24:88-90.
[15] Romero-Gomez M, Zelber-Sagi S, Trenell M.Treatment of NAFLD with diet, physical activity and exercise.J Hepatol, 2017, 67:829-846.
[16] Machado MV, Diehl AM.Pathogenesis of nonalcoholic steatohepatitis.Gastroenterology, 2016, 150:1769-1777.
[17] 梁煜, 李俊杰, 梁卓林, 等.双环醇片对来曲唑治疗乳腺癌患者伴发脂肪肝的预防作用研究.实用药物与临床, 2016, 19:1490-1492.
[18] Bao XQ, Liu GT.Induction of overexpression of the 27-and 70-kDa heat shock proteins by bicyclol attenuates concanavalin a-induced liver injury through suppression of nuclear factor-kB in mice. Mol Pharmacol, 2009, 75:1180-1188.
[19] Liu GT. Inhibition of Fas/FasL mRNA expression and TNF-α release in concanavalin A-induced liver injury in mice by bicyclol. World J Gastroentero, 2004, 10:1775-1779.
[20] Yu HY, Wang BL, Zhao J, et al. Protective effect of bicyclol on etracycline-induced fatty liver in mice. Toxicology, 2009, 261:112-118.
[21] Hu QW, Liu GT. Effects of bicyclol on dimethylnitrosamineinduced liver fibrosis in mice and its mechanism of action. Life Sci, 2006, 79:606-612.
[22] Gu Y, Zhao J, Yao XM, et al. Effects of bicyclol on immunological liver fibrosis in rats . J Asian Nat Prod Res, 2010, 12:388-398.